Since its introduction in France as an experimental medical treatment, medical cannabis has attracted growing interest. As it enters its third year of trial in the country, many questions remain about this new therapeutic approach. Medical cannabis, which involves using cannabis extracts for medical purposes, has prompted both enthusiasm and questions within the medical community and society at large. What is medical cannabis? What are the conditions for its use in France? What results have been achieved so far? These are just some of the questions that need to be answered to better understand the issues and challenges surrounding this new form of treatment. In this article, we take a closer look at medical cannabis in France, examining its regulatory framework, medical applications and future prospects.
When is medical cannabis used as a treatment?
The use of medical cannabis in France is strictly regulated by the French National Agency for the Safety of Medicines and Health Products (ANSM). According to ANSM guidelines, medical cannabis may only be prescribed for five specific indications. First, it may be used to treat neuropathic pain that has not responded to other therapies. It may also be prescribed for severe epilepsy that is resistant to conventional medicines. In addition, medical cannabis may be used to treat certain intractable symptoms in oncology, such as pain and nausea. It may also be used to relieve painful spasticity associated with multiple sclerosis or other conditions affecting the central nervous system. Finally, medical cannabis may be used in palliative care to relieve symptoms associated with serious, advanced-stage illnesses.
It is important to note that medical cannabis is not a first-line treatment, but is offered when other forms of care have proved ineffective or poorly tolerated. According to Nathalie Richard, head of the medical cannabis project at ANSM, “Cannabis is not a first-line treatment. It is offered when other forms of care prove ineffective or poorly tolerated.” The expected effects of medical cannabis include muscle relaxation to help patients cope with their illness, manage pain and improve sleep, as well as other potential benefits.
It is also important to note that medical cannabis is not limited to adults and may also be used by children, particularly to treat epilepsy. However, the use of medical cannabis in children is also strictly regulated by ANSM and must be approached with caution and under appropriate medical supervision. In short, the use of medical cannabis in France is limited to specific indications and is subject to rigorous monitoring and regulation by ANSM to ensure that this new therapeutic approach is used safely and effectively.
Can patients apply to take part in the medical cannabis trial?
To take part in the medical cannabis trial in France, patients must contact a doctor working at one of the 324 hospital referral centres listed on the website of the French National Agency for the Safety of Medicines and Health Products (ANSM). By 24 February, 2,462 patients had taken part in the trial. Once the initial follow-up has been completed, the patient’s GP can take over. Medical cannabis is dispensed by pharmacies, either in hospitals or in the community.
It is important to note that all healthcare professionals involved in the trial must first receive training on the specific characteristics of the product to ensure that medical cannabis is used appropriately and safely.
What forms does medical cannabis treatment come in?
Medical cannabis can be taken as an oil or dried flowers. The oil is generally used as a long-term treatment and is taken orally, while the flowers are administered by inhalation using a specific vaporiser, which heats them to around 180 °C without combustion. There are three types of medical cannabis, distinguished by their tetrahydrocannabinol (THC) and cannabidiol (CBD) ratios, according to Nathalie Richard, head of the medical cannabis project at ANSM. These are THC-dominant, used mainly for pain relief; CBD-dominant, used for its anti-epileptic properties; and a balanced version containing both THC and CBD. Dosage is based on the experience of countries such as Canada and the Netherlands, where medical cannabis has been used for a long time.
It is important to note that medical cannabis must be prescribed on a secure prescription form and the prescription must not exceed twenty-eight days, in accordance with the rules on controlled drugs. In addition, unlike CBD sold over the counter, the titration and quality of the CBD used in medical cannabis are systematically checked to ensure the safety and effectiveness of the treatment.
Where do medical cannabis products come from?
Medical cannabis products are mainly imported from countries such as Australia, Canada, Portugal and Israel. These foreign suppliers must comply with strict standards set out in detailed specifications, and each supplier is partnered with a French pharmaceutical laboratory to oversee operations. In addition, the products are regularly checked by laboratories of the French National Agency for the Safety of Medicines and Health Products (ANSM) to ensure their quality in line with the requirements for medicines. However, it is worth noting that a decree published in February now authorises the cultivation of medical cannabis in France, which could potentially change the exclusive import supply chain in the coming years.
What are the results after two years of the medical cannabis trial?
The two-year review of the medical cannabis trial is based on a national electronic monitoring register called Recann, which healthcare professionals complete at each consultation for every patient. This monitoring system collects precise and comprehensive data on both the benefits and the problems experienced by patients.
According to Nathalie Richard, no new risks have been identified beyond those already known. During the first twenty months of the trial, 2,282 adverse events, including 59 serious cases, were reported in the register. The main adverse events are related to disorders of the central nervous system (dizziness, drowsiness...), gastrointestinal problems (nausea, constipation...) and psychiatric effects (depression...).
According to the data collected, there have been very few cases of addiction in this closely monitored setting. It is important to note that Recann allows adverse events to be closely monitored and treatments adjusted accordingly, helping to ensure the safety of patients receiving medical cannabis.
Thus, the two-year review of the medical cannabis trial shows that the data collected through the national monitoring register are accurate and make it possible to identify adverse effects, with no new major risks identified beyond those already known. The risk of addiction is also limited under this closely monitored trial.
No risk of misuse: The medical cannabis trial in France is subject to strict monitoring to prevent any misuse.
In France, the sale and use of recreational cannabis are illegal, although the French are the biggest consumers in Europe. However, medical cannabis is considered a medicine and is subject to a trial approved by the National Assembly in late 2019. The trial is supervised by the French National Agency for Medicines and Health Products Safety (ANSM) and overseen by a temporary scientific monitoring committee made up of doctors, patients and pharmacovigilance representatives.
Thanks to this rigorous monitoring, the ANSM states that there is no misuse of medical cannabis in France. Data are recorded in a national electronic monitoring register (Recann), completed by healthcare professionals at every consultation for each patient, making it possible to detect any adverse effects or potential problems. To date, this enhanced monitoring system has minimised the risk of medical cannabis being used illicitly in France.
How effective is the treatment?
The effectiveness of the treatment is not assessed using precise figures as part of the current trial. This is because the trial is not a clinical study designed to assess the benefit-risk balance of medical cannabis, but rather a way of testing new public policies. Nevertheless, doctors regularly ask patients about how well they tolerate the product and any improvements it brings during consultations, which take place at least monthly when prescriptions are renewed. So far, 277 patients, or 12% of the total, have left the trial because the treatment was ineffective (statistics as at 13/12/2022). Feedback collected in the monitoring register is generally encouraging, with positive results reported for painful spasticity associated with multiple sclerosis, particularly in terms of relief from spasms and pain, as well as good tolerability, according to the ANSM's latest report. A scientific committee also meets regularly to discuss the value of medical cannabis and compare the information collected with the findings of similar studies in the field.
Why has the medical cannabis trial been extended?
Initially planned to run for two years, the medical cannabis trial has been extended until 26 March 2024 because health authorities require further information about its effectiveness. The aim for the coming year is to include new patients and collect a more substantial body of data. However, it is worth noting, as Nathalie Richard points out, that the scientific literature on medical cannabis and experience from other countries are conclusive. A small number of clinical trials are also under way in France alongside the trial. The conditions for covering the cost of medical cannabis have yet to be determined. Extending the trial will therefore make it possible to continue collecting data to better assess its effectiveness and use in the medical context in France.
What conclusions can be drawn?
In conclusion, given the information collected so far and the potential benefits of medical cannabis, it is essential that the trial continues to progress in France. Although the trial may have been extended because more data on its effectiveness need to be collected, existing scientific literature and experience from other countries support its medical use. The encouraging results observed in some patients, along with ongoing clinical trials, underline the importance of continuing to explore the therapeutic potential of medical cannabis for specific health conditions. It is therefore crucial to continue monitoring this trial closely and to promote research and a deeper understanding of the potential benefits of medical cannabis in France.